Pfizer has reached agreements with several generic drug manufacturers that will allow its heart medicine Vyndamax to remain free from generic competition in the United States until 2031. The move gives the company more time to maintain strong sales from one of its key treatments while delaying lower-cost alternatives from entering the market.
Vyndamax is used to treat transthyretin amyloid cardiomyopathy (ATTR-CM), a rare heart disease treatment that helps manage a condition affecting the body’s ability to function properly over time. The medicine has become an important part of Pfizer’s cardiovascular drug portfolio and is considered one of the company’s top-performing products.
The agreements settle patent dispute cases between Pfizer and generic drugmakers, including Dexcel Pharma, Hikma Pharmaceuticals, and Cipla. These companies had challenged Pfizer’s patents in court, seeking approval to launch more affordable versions of the drug before the patent period ended.
Under the settlement terms, generic versions of Vyndamax cannot be sold in the U.S. before June 2031, unless future legal decisions change the timeline. This means Pfizer will continue to have exclusive rights to market the drug for several more years.
Also Read: Profluent & Lilly Join Hands in 2.25 Billion USD Genetic Medicine Deal
The decision is financially important for Pfizer. Vyndamax and related products generated billions of dollars in pharmaceutical industry sales in recent years, helping support the company’s revenue as it faces patent expirations on other major medicines. Keeping the drug protected until 2031 provides Pfizer with a longer period to earn revenue from the treatment.
The agreement also comes at a time when many large drug companies are working to defend their patents and delay generic medicine competition. Patent settlements are common in the healthcare industry because they can help companies avoid lengthy legal battles while offering more certainty about future sales.
Industry experts believe the extended drug patent protection period could help Pfizer better manage upcoming revenue challenges linked to other medicines nearing patent expiry. It also gives the company more time to invest in research, develop new treatments, and strengthen its future product pipeline.
For patients, however, the delay in affordable medicines entering the market means lower-cost alternatives to Vyndamax may not be available for several more years.
.jpg)
.jpg)
